{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:09:20Z","timestamp":1767773360793,"version":"3.40.5"},"reference-count":50,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.dld.2024.05.021","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T15:53:46Z","timestamp":1718294026000},"page":"2060-2068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6211-1422","authenticated-orcid":false,"given":"Patricia","family":"Sanz Segura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0076-3529","authenticated-orcid":false,"given":"Fernando","family":"Gomoll\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Casas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa","family":"Iborra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milagros","family":"Vela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Fern\u00e1ndez-Clotet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8833-5424","authenticated-orcid":false,"given":"Roser","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Garc\u00eda de la Filia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Garc\u00eda Prada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan \u00c1ngel","family":"Ferrer Rosique","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"de Francisco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Arias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iv\u00e1n","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1176-276X","authenticated-orcid":false,"given":"\u00c1ngel","family":"Ponferrada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier P.","family":"Gisbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Carrillo-Palau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Calvet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"M\u00e1rquez-Mosquera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Gros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4589-9497","authenticated-orcid":false,"given":"Fiorella","family":"Ca\u00f1ete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Monfort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3091-2361","authenticated-orcid":false,"given":"Rosa Eva","family":"Madrigal Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d3scar","family":"Roncero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Laredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7676-9842","authenticated-orcid":false,"given":"Miguel","family":"Montoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7748-6606","authenticated-orcid":false,"given":"Beatriz","family":"L\u00f3pez-Cauce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rufo","family":"Lorente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Fuentes Coronel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1872-0917","authenticated-orcid":false,"given":"Dolores","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Varela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonsoles","family":"Olivares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Pajares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1183-1072","authenticated-orcid":false,"given":"Alfredo J.","family":"Lucendo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Ses\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Botella Mateu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Nos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugeni","family":"Dom\u00e8nech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3970-5457","authenticated-orcid":false,"given":"Santiago","family":"Garc\u00eda-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dld.2024.05.021_bib0001","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","article-title":"Inflammatory bowel disease: pathogenesis","volume":"20","author":"Zhang","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"10","key":"10.1016\/j.dld.2024.05.021_bib0002","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/ueg2.12319","article-title":"Environmental risk factors for inflammatory bowel disease","volume":"10","author":"Singh","year":"2022","journal-title":"United European Gastroenterol J"},{"issue":"2","key":"10.1016\/j.dld.2024.05.021_bib0003","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.cyto.2014.12.014","article-title":"Cytokines in psoriasis","volume":"73","author":"Baliwag","year":"2015","journal-title":"Cytokine"},{"issue":"11","key":"10.1016\/j.dld.2024.05.021_bib0004","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/ijd.13691","article-title":"Development of paradoxical inflammatory disorders during treatment of psoriasis with TNF inhibitors: a review of published cases","volume":"56","author":"Havmose","year":"2017","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.dld.2024.05.021_bib0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jaad.2020.01.006","article-title":"Histologic comparison of tumor necrosis factor-\u03b1 inhibitor-induced psoriasis and psoriasis vulgaris","volume":"83","author":"Hu","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.dld.2024.05.021_bib0006","first-page":"e42791","article-title":"Paradoxical Tumor Necrosis Factor-Alpha (TNF-\u03b1) Inhibitor-Induced Psoriasis: a Systematic Review of Pathogenesis, Clinical Presentation, and Treatment","volume":"15","author":"Chokshi","year":"2023","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.dld.2024.05.021_bib0007","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40257-017-0296-7","article-title":"Clinical signs, pathophysiology and management of cutaneous side effects of anti-tumor necrosis factor agents","volume":"18","author":"Segaert","year":"2017","journal-title":"Am J Clin Dermatol"},{"issue":"9625","key":"10.1016\/j.dld.2024.05.021_bib0008","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2024.05.021_bib0009","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.dld.2024.05.021_bib0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ecco-jcc\/jjz110","article-title":"IM-UNITI: three-year efficacy, safety and immunogenicity of ustekinumab treatment of Crohn's Disease","volume":"14","author":"Hanauer","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"13","key":"10.1016\/j.dld.2024.05.021_bib0011","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.dld.2024.05.021_bib0012","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/ibd\/izab201","article-title":"Efficacy of Ustekinumab in Crohn's Disease with and without concurrent autoimmune skin disease","volume":"28","author":"Fradkov","year":"2022","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"10.1016\/j.dld.2024.05.021_bib0013","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/ecco-jcc\/jjaa260","article-title":"Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review","volume":"15","author":"Guillo","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"2","key":"10.1016\/j.dld.2024.05.021_bib0014","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/2475530318810851","article-title":"TNF Inhibitor-Induced Psoriasis: proposed algorithm for treatment and management","volume":"4","author":"Li","year":"2019","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"12","key":"10.1016\/j.dld.2024.05.021_bib0015","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/ijd.14072","article-title":"Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review","volume":"57","author":"Melo","year":"2018","journal-title":"Int J Dermatol"},{"issue":"11","key":"10.1016\/j.dld.2024.05.021_bib0016","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/apt.16883","article-title":"Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease","volume":"55","author":"Townsend","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.dld.2024.05.021_bib0017","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.gastrohep.2020.05.007","article-title":"en representaci\u00f3n de GETECCU. The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory bowel disease) by GETECCU: design, monitoring and functions","volume":"43","author":"Zabana","year":"2020","journal-title":"Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.dld.2024.05.021_bib0018","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"12","key":"10.1016\/j.dld.2024.05.021_bib0019","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1038\/ajg.2017.416","article-title":"Research to the N-power: the strengths of networked clinical collaboration in Spain","volume":"112","author":"McNicholl","year":"2017","journal-title":"Am J Gastro"},{"issue":"8167","key":"10.1016\/j.dld.2024.05.021_bib0020","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn's-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.dld.2024.05.021_bib0021","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis","volume":"132","author":"D'Haens","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.05.021_bib0022","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1365-2133.2004.06107.x","article-title":"Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases","volume":"151","author":"Dereure","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.dld.2024.05.021_bib0023","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ard.2007.087288","volume":"68","author":"Harrison","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.dld.2024.05.021_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","article-title":"Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients","volume":"9","author":"Wollina","year":"2008","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.dld.2024.05.021_bib0025","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/apt.14822","article-title":"Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study","volume":"48","author":"Bae","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dld.2024.05.021_bib0026","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1586\/1744666X.2014.866038","article-title":"Paradoxical effects of anti-TNF-\u03b1 agents in inflammatory diseases","volume":"10","author":"Wendling","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10.1016\/j.dld.2024.05.021_bib0027","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview","volume":"2","author":"Toussirot","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.dld.2024.05.021_bib0028","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.3389\/fimmu.2018.02746","article-title":"Psoriasis: classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon","volume":"9","author":"Mylonas","year":"2018","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.dld.2024.05.021_bib0029","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.dld.2024.05.021_bib0030","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jaad.2008.10.062","article-title":"Trends in incidence of adult onset psoriasis over three decades: a population based study","volume":"60","author":"Icen","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.dld.2024.05.021_bib0031","doi-asserted-by":"crossref","first-page":"492","DOI":"10.2340\/00015555-0711","article-title":"Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis","volume":"89","author":"Wolk","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.dld.2024.05.021_bib0032","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","article-title":"Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-\u03b3-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment","volume":"63","author":"Tillack","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.dld.2024.05.021_bib0033","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1007\/s10620-015-3763-0","article-title":"Psoriasiform skin lesions are caused by anti-TNF agents used for the treatment of inflammatory bowel disease","volume":"60","author":"George","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2024.05.021_bib0034","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.crohns.2013.10.013","article-title":"The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series","volume":"8","author":"Afzali","year":"2014","journal-title":"J Crohn's Colitis"},{"issue":"21","key":"10.1016\/j.dld.2024.05.021_bib0035","doi-asserted-by":"crossref","first-page":"7873","DOI":"10.3390\/ijms21217873","article-title":"Paradoxical psoriasis induced by Anti-TNF\u03b1 treatment: evaluation of disease-specific clinical and genetic markers","volume":"21","author":"Bucalo","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.dld.2024.05.021_bib0036","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.crohns.2012.08.007","article-title":"Induction or exacerbation of psoriatic lesions during anti-TNF-\u03b1 therapy for inflammatory bowel disease: a systematic literature review based on 222 cases","volume":"7","author":"Denadai","year":"2013","journal-title":"J Crohns Colitis"},{"issue":"4","key":"10.1016\/j.dld.2024.05.021_bib0037","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/MIB.0000000000000757","article-title":"ENEIDA project). Incidence, clinical characteristics, and management of psoriasis induced by Anti-TNF therapy in patients with inflammatory bowel disease: a Nationwide Cohort Study","volume":"22","author":"Guerra","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2024.05.021_bib0038","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10020364","article-title":"Dermatological manifestations in inflammatory bowel diseases","volume":"10","author":"Antonelli","year":"2021","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.dld.2024.05.021_bib0039","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/MEG.0000000000001917","article-title":"Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy","volume":"33","author":"Nigam","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.05.021_bib0040","first-page":"jjac035","article-title":"How to manage inflammatory bowel disease patients when they withdraw anti-TNF due to severe anti-TNF-induced skin lesions? A multicenter cohort study","author":"Cottron","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"2","key":"10.1016\/j.dld.2024.05.021_bib0041","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaad.2016.08.012","article-title":"Tumor necrosis factor-\u03b1 inhibitor induced psoriasis: systematic review of clinical features, histopathological findings, and management experience","volume":"76","author":"Brown","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.dld.2024.05.021_bib0042","doi-asserted-by":"crossref","first-page":"e14225","DOI":"10.1111\/dth.14225","article-title":"Tumor necrosis factors-\u03b1 inhibition-induced paradoxical psoriasis: a case series and literature review","volume":"33","author":"Lian","year":"2020","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.dld.2024.05.021_bib0043","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ajg.2016.54","article-title":"The risk of relapse after ANTI-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis","volume":"111","author":"Gisbert","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.dld.2024.05.021_bib0044","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/00365521.2019.1582693","article-title":"Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy","volume":"54","author":"Bots","year":"2019","journal-title":"Scand J Gastroenterol"},{"issue":"12","key":"10.1016\/j.dld.2024.05.021_bib0045","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/apt.16361","article-title":"(EVODIS Study Group*). Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study","volume":"53","author":"Casanova","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dld.2024.05.021_bib0046","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2468-1253(22)00385-5","article-title":"GETAID and the SPARE-Biocycle research group. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial","volume":"8","author":"Louis","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2024.05.021_bib0047","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial [PHOENIX 1]","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2024.05.021_bib0048","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial [PHOENIX 2]","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.dld.2024.05.021_bib0049","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.dld.2016.08.122","article-title":"Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti-TNF-alpha therapy-induced dermatological side effects","volume":"48","author":"Pijls","year":"2016","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.dld.2024.05.021_bib0050","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3748\/wjg.v22.i3.1017","article-title":"How to predict clinical relapse in inflammatory bowel disease patients","volume":"22","author":"Liverani","year":"2016","journal-title":"World J Gastroenterol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824007795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824007795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T09:10:12Z","timestamp":1732525812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865824007795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1590865824007795"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2024.05.021","relation":{},"ISSN":["1590-8658"],"issn-type":[{"type":"print","value":"1590-8658"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2024.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}